Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that applies proven science to revolutionize treatments, starting with eye care. The company's flagship product, XDEMVY (lotilaner ophthalmic solution) 0.25%, received FDA approval as the first and only treatment for Demodex blepharitis, an eyelid disease caused by Demodex mites. Beyond its commercialized ophthalmic product, Tarsus is advancing a clinical pipeline targeting other therapeutic categories, including dermatology and infectious disease prevention. Key pipeline candidates include TP-04, an ophthalmic gel for the potential treatment of ocular rosacea, and TP-05, an oral tablet being evaluated for the prevention of Lyme disease. Headquartered in Irvine, California, the company leverages its expertise in drug development to address highly prevalent conditions with limited existing treatment alternatives.
